Paxlovid may not reduce risk for long COVID, study shows

Paxlovid did not reduce the risk for long COVID among vaccinated, nonhospitalized people who received it within a month of their first SARS-CoV-2 infection, a study showed.
The FDA approved Paxlovid in May 2023 for adults at risk for severe COVID-19, making it the first oral antiviral to gain full approval to treat the disease, although it was available under an emergency use authorization for more than a year before that.
In the new study, researchers at the University of California, San Francisco (UCSF) found that the risk for long COVID was relatively similar between people treated with

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart